• metastatic/advanced NSCLC (mNSCLC) - 1st line (L1)
• mNSCLC - L1 - all population 5
• mNSCLC - L1 - EGFR mutant
• mNSCLC - L1 - PDL1 negative 1
• mNSCLC - L1 - PDL1 positive 14
• mNSCLC - L1 - TMB>10Mb 1
• non squamous cell - mNSCLC - L1
• non squamous - mNSCLC - L1 - all population 3
• non squamous - mNSCLC - L1 - PDL1 positive
• non squamous - mNSCLC - L1 - Wild Type (WT) 6
• squamous cell - mNSCLC - L1
• squamous - mNSCLC - L1 - all population 4
• squamous - mNSCLC - L1 - PDL1 positive
• squamous - mNSCLC - L1 - Wild Type (WT)

 

• immune chekpoint inhibitors
• anti-PD-(L)1
• cemiplimab
• durvalumab based treatment
• durvalumab alone
• sintilimab based treatment
• sintillimab plus SoC
• Immune checkpoint association
• durvalumab plus tremelimumab
• nivolumab plus ipilimumab
• nivolumab plus ipilimumab plus SoC

• versus all
• vs chemotherapy
• vs Standard of Care (SoC)
• vs placebo plus SoC

  All patients PDL1 (TC0 and IC0 : <1% of TC and IC) PDL1 (TC1/2/3 or IC1/2/3 : ≥1% of TC or IC) PDL1 (TC3 or IC3 : ≥50% of TC or ≥10% of IC )

• study list
• mapping
• overview
• meta-analysis
• forest plot
• NMA
• excluded

Top evidence (RCT only, high risk of bias excluded) Best available evidence (possibly low or very low) All RCTs All studies (RCT+OBS)   studies

mNSCLC - L1 - all population, durvalumab plus tremelimumab vs. all, meta-analysis of study results

TE: relative treatment effect (measured by a risk ratio, an odds ratio or an hazard ratio depending on what is reported in the papers); k: number of studies; n: total number of patients; ROB: risk of bias (ROB 2.0); Pub. bias: publication bias; OBS: observational studies; RCT: randomized clinical trials
studied treatment is better when TE > 1; studied treatment is better when TE < 1;